Keyphrases
Lopinavir
100%
Drug Combination
100%
Hydroxychloroquine
100%
Azithromycin
87%
Doxycycline
68%
Surabaya
55%
Dual Drug
54%
Indonesia
54%
Randomized Double-blind
50%
Moderate COVID-19
50%
Multicenter Clinical Trial
50%
Pranayama
50%
COVID-19 Infection
50%
Training Exercise
50%
Endurance Training
50%
Antiviral Agents
50%
Antibiotics
50%
Asthma Symptoms
50%
In Vitro Study
50%
Peak Expiratory Flow
50%
Hospitalized Patients
50%
SARS-CoV-2 Virus
50%
Yoga Exercise
50%
Endurance Exercise
38%
Asthma Control
22%
Favipiravir
18%
Intervention Group
16%
Interleukin-10
15%
COVID-19
15%
Treatment Group
13%
Clarithromycin
12%
Cytotoxicity
12%
Universitas
11%
Yoga
11%
Interleukin-6
10%
Safe Use
6%
Antiviral Efficacy
6%
Anti-inflammatory Response
6%
Writing Research
6%
COVID-19 Infectious Disease
6%
Vero Cells
6%
CC50
6%
Incubation
6%
Low Cytotoxicity
6%
Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs)
6%
Commercially Available
6%
Quantitative PCR
6%
Virus
6%
Inoculation
6%
Viral Load
6%
Descending Order
6%
IC50
6%
Antiviral Activity
6%
IC50 Value
6%
Inflammatory Markers
6%
Viral
6%
COVID-19 Treatment
6%
Copy number
6%
Forced Expiratory Maneuver
5%
Maximum Flow
5%
Total Lung Capacity
5%
Asthma
5%
Training Session
5%
Purposive Sampling Technique
5%
Asthma Patients
5%
General Hospital
5%
Pharmacological Therapy
5%
Calm
5%
East Java
5%
Inclusion Criteria
5%
Significance Value
5%
Lung Capacity
5%
Trainer
5%
Group Design
5%
Pretest-posttest
5%
Complementary Therapies
5%
Forced Vital Capacity
5%
Inhalation
5%
Forced Expiration
5%
Pharmacology, Toxicology and Pharmaceutical Science
Hydroxychloroquine
100%
Combination Drug
100%
Lopinavir Plus Ritonavir
100%
Azithromycin
87%
Doxycycline
68%
Infection
50%
SARS Coronavirus
50%
Antivirus Agent
50%
Clinical Study
50%
Antibiotics
50%
Favipiravir
18%
Cytotoxicity
18%
Tumor Necrosis Factor
15%
Interleukin 10
15%
Interleukin 6
15%
Treatment Group
13%
Clarithromycin
12%
IC50
12%
Diseases
12%
Coronavirinae
6%
Inflammation
6%
Anti-Inflammatory Drug
6%
Antiviral Activity
6%